AMDA: Don’t prescribe Aduhelm to long-term care residents without more testing
By
Alicia Lasek
Jul 01, 2021
“It is our responsibility to resist the urge to prescribe a potentially dangerous and ineffective medication that is untested in our population, even if it has FDA approval,” the LTC physician’s...
To save itself, might Medicare deny coverage of controversial new Alzheimer’s drug?
By
Kimberly Marselas
Jun 28, 2021
The true price to administer aducanumab — a controversial new Alzheimer’s treatment — may actually be closer to $100,000 annually than other, lower estimates and is just one reason the Centers for...